{"gene":"NRAS","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":1983,"finding":"A single nucleotide change at codon 61 of N-ras (glutamine to lysine substitution) activates its transforming potential, establishing that point mutations at codon 61 (and previously identified codon 12) are sufficient for oncogenic activation.","method":"Gene cloning, DNA sequencing, NIH 3T3 transformation assay","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct sequencing plus functional transformation assay, foundational paper replicated across many subsequent studies","pmids":["6616621"],"is_preprint":false},{"year":1985,"finding":"Oncogenic N-ras (codon 61, glutamine to histidine) was cloned from a rhabdomyosarcoma cell line; a mutation at position 61 (CAA to CAT) is sufficient for transforming activity, confirming codon 61 as a key activation site.","method":"Gene cloning, chimeric recombinant construction, DNA sequencing, NIH 3T3 transformation assay","journal":"International journal of cancer","confidence":"High","confidence_rationale":"Tier 1 / Strong — functional transformation assay combined with sequencing; replicates the codon 61 finding from multiple labs","pmids":["3158613"],"is_preprint":false},{"year":1985,"finding":"Activation of N-ras in melanoma cells involves a codon 61 mutation (glutamine to lysine), and only clones carrying this mutation are biologically active in transfection assays.","method":"Southern blot, oligonucleotide hybridization, DNA sequencing, transfection/transformation assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct sequencing plus functional transformation assay, replicated across labs","pmids":["3887133"],"is_preprint":false},{"year":1987,"finding":"Normal and mutant (Gly-12, Asp-12, Val-12) human N-ras p21 proteins were produced in E. coli; mutant proteins showed reduced GTPase activity (Val-12 retains 12%, Asp-12 retains 43% of wild-type) while both were equally potent in inducing morphological transformation, indicating reduced GTPase rather than altered nucleotide binding drives oncogenicity.","method":"Recombinant protein production in E. coli, GTPase activity assay, guanine nucleotide binding assay, microinjection into NIH 3T3 cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted in vitro enzymatic assay with mutagenesis and functional cellular readout","pmids":["3550423"],"is_preprint":false},{"year":1987,"finding":"Oncogenic forms of N-ras (but not the proto-oncogenic form) completely suppress skeletal myoblast differentiation (fusion, muscle-specific gene expression including nicotinic acetylcholine receptor and creatine kinase) in C2 cells at the level of mRNA accumulation, independently of effects on cell proliferation.","method":"DNA-mediated gene transfer into mouse C2 skeletal muscle cells, analysis of muscle-specific mRNA and protein markers","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean gain-of-function with defined molecular readout; proto-oncogene vs oncogene comparison as internal control","pmids":["3600660"],"is_preprint":false},{"year":1997,"finding":"In the presence of farnesyl protein transferase inhibitors, N-Ras (unlike H-Ras) is alternatively prenylated by geranylgeranyl transferase-1 and remains associated with the membrane fraction, explaining why FTIs fail to displace N-Ras from membranes.","method":"Cell-based prenylation assay in COS cells and DLD-1 colon carcinoma cells; membrane fractionation; FTI treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct biochemical fractionation with isoform-by-isoform comparison, replicated in two cell systems","pmids":["9162087"],"is_preprint":false},{"year":1997,"finding":"S-palmitoylation of the farnesylated C-terminal peptide of N-ras stabilizes membrane association and mediates plasma membrane targeting; the S-acylated form localizes preferentially to the plasma membrane in CV-1 cells, and this localization is maintained by a 'kinetic trapping' mechanism at the plasma membrane itself, not through the secretory pathway.","method":"Fluorescent lipid-modified peptide reconstitution with liposomes, cell culture uptake assay, fluorescence microscopy, brefeldin A and low-temperature treatments","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted peptide system with orthogonal fluorescence microscopy and pharmacological perturbation; single lab","pmids":["9335573"],"is_preprint":false},{"year":1998,"finding":"Ras-GRF/Cdc25Mm selectively activates Ha-Ras but not N-Ras or K-Ras 4B in vivo; the C-terminal hypervariable domain of Ras proteins dictates this GEF specificity, indicating that Ras isoforms can engage distinct upstream activators.","method":"In vivo Ras activation assay in cells, GEF selectivity assay, C-terminal domain analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single lab, single method demonstrating differential GEF activation; domain mapping provides partial mechanistic support","pmids":["9430727"],"is_preprint":false},{"year":1998,"finding":"In Ha-ras-transformed fibroblasts, Raf-1 co-immunoprecipitates with endogenous c-N-Ras but not with (G12V)Ha-Ras, suggesting N-Ras has higher affinity for Raf-1 than Ha-Ras in vivo; antisense knockdown of c-N-Ras abrogates constitutive MAPK activity of Ha-ras-transformed cells, demonstrating that c-N-Ras function is required for Ha-Ras-driven MAPK signaling.","method":"Co-immunoprecipitation, antisense oligonucleotide knockdown, MAPK activity assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP combined with functional knockdown; single lab, two orthogonal approaches","pmids":["9525741"],"is_preprint":false},{"year":1999,"finding":"Transforming N-Ras(K61) mutant expression in NRK cells causes fragmentation and collapse of the Golgi complex, disruption of the actin cytoskeleton, and increased constitutive protein transport from the trans-Golgi network to the cell surface; these effects are partially inhibited by a phospholipase A2 inhibitor.","method":"Conditional expression system, electron microscopy, stereological analysis, protein transport assay, pharmacological inhibition","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional expression with ultrastructural and functional readouts; single lab, multiple orthogonal methods","pmids":["9914160"],"is_preprint":false},{"year":2001,"finding":"Calmodulin binds to K-Ras but not to N-Ras or H-Ras, as demonstrated by calmodulin affinity chromatography; calmodulin inhibition preferentially activates K-Ras, not N-Ras.","method":"Calmodulin affinity chromatography from cellular lysates, Ras activation assay","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct affinity chromatography with isoform comparison; negative result for N-Ras binding is mechanistically informative; single lab","pmids":["11585916"],"is_preprint":false},{"year":2005,"finding":"DHHC9 and GCP16 form a protein complex that functions as a human protein palmitoyltransferase with substrate specificity for H-Ras and N-Ras but not for myristoylated Gαi1 or GAP-43; DHHC9 requires GCP16 for enzymatic activity and protein stability; the complex co-distributes in the Golgi apparatus.","method":"Purified DHHC9·GCP16 complex palmitoyltransferase assay in vitro, co-immunoprecipitation, subcellular localization by microscopy","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted in vitro palmitoyltransferase assay with substrate specificity determination plus co-IP and localization; functional analog validated against yeast ortholog","pmids":["16000296"],"is_preprint":false},{"year":2006,"finding":"N-Ras lipidated protein partitions preferentially into liquid-disordered (ld) lipid domains rather than liquid-ordered (lo) or solid-ordered (so) domains, with the phase preference order ld > lo >> so; additionally, a large proportion localizes at the ld/lo phase boundary, suggesting an interfacial adsorption mechanism.","method":"Two-photon fluorescence microscopy on giant unilamellar vesicles, tapping-mode atomic force microscopy with fully lipidated (hexadecylated and farnesylated) fluorescent N-Ras protein","journal":"Journal of the American Chemical Society","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted fully lipidated protein with two independent orthogonal biophysical methods (fluorescence microscopy + AFM); single lab","pmids":["16390147"],"is_preprint":false},{"year":2009,"finding":"pRb inactivation induces E2F-dependent upregulation of farnesyl diphosphate synthase and prenyltransferases, leading to enhanced isoprenylation and activation of N-Ras; elevated N-Ras activity induces DNA damage response and p130-dependent cellular senescence in Rb-deficient cells.","method":"Genetic mouse model (Rb heterozygous), E2F-dependent gene expression analysis, N-Ras activity assay, senescence assays","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic model combined with biochemical pathway analysis; single lab, multiple readouts","pmids":["19345325"],"is_preprint":false},{"year":2010,"finding":"Acquired resistance to PLX4032 (B-RAF V600E inhibitor) develops via N-RAS mutations (but not secondary B-RAF mutations), causing high levels of activated N-RAS that lead to significant MAPK pathway reactivation; knockdown of N-RAS reduced growth of resistant cells, and overexpression of N-RAS(Q61K) conferred PLX4032 resistance to sensitive cells.","method":"Drug-resistant cell line derivation, N-RAS mutation detection, N-RAS knockdown, N-RAS overexpression, MAPK pathway activity assays, validation in patient-derived biopsies","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function and gain-of-function with mechanistic pathway readout, validated in clinical specimens; reciprocal experimental design","pmids":["21107323"],"is_preprint":false},{"year":2011,"finding":"TLR agonists at the plasma membrane (TLR 1, 2, 4, 5, 6) rapidly activate N-Ras but not other Ras isoforms in cholangiocytes; activated N-Ras signals through ERK1/2 to drive IL-6 secretion and cholangiocyte proliferation; TRAF6 depletion does not affect N-Ras activation, indicating a TRAF6-independent TLR-to-N-Ras pathway.","method":"Ras activation assay (isoform-selective), RNAi knockdown of N-Ras and TRAF6, luciferase reporter for IL-6 promoter, MEK/ERK inhibitors, proliferation assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-selective activation assay plus RNAi with multiple downstream readouts; single lab","pmids":["21757746"],"is_preprint":false},{"year":2011,"finding":"Clustering of raft-associated proteins (GPI-anchored HA-GPI or fibronectin receptors) selectively enhances plasma membrane-to-cytoplasm exchange of GTP-bound N-Ras in a cholesterol-dependent manner; this effect depends strictly on depalmitoylation; HA-GPI clustering enhances Golgi accumulation and EGF-stimulated N-Ras-GTP signaling.","method":"Patch-FRAP, FRAP beam-size analysis, electron microscopy, cholesterol depletion, palmitoylation-deficient mutants","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal biophysical methods (patch-FRAP, EM) with mutagenesis (palmitoylation-deficient mutants) and pharmacological validation; single lab","pmids":["21807892"],"is_preprint":false},{"year":2011,"finding":"Membrane binding of lipidated N-Ras induces new conformational substates in the protein (detected as novel FTIR bands) beyond those induced by nucleotide binding; the membrane acts as an active interaction partner that controls G-domain orientation and selection of signaling conformations.","method":"Pressure-modulation FTIR spectroscopy, ATR-FTIR and IRRAS measurements on lipidated N-Ras in solution and membrane-bound states","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — rigorous biophysical method (pressure-FTIR) revealing novel conformational substates, but single lab and no mutagenesis follow-up reported","pmids":["22203965"],"is_preprint":false},{"year":2012,"finding":"Mutant N-RAS protects colorectal cancer cells from apoptosis via activation of a noncanonical MAPK pathway signaling through STAT3; MEK inhibition selectively induces apoptosis in colonic tumors expressing mutant N-RAS.","method":"Genetically engineered mouse model, STAT3 pathway analysis, MEK inhibitor treatment, apoptosis assays","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic model with defined mechanistic pathway (N-RAS → noncanonical MAPK → STAT3) and pharmacological validation; single lab but multiple orthogonal approaches","pmids":["23274911"],"is_preprint":false},{"year":2013,"finding":"Palmitoylation of N-Ras is required for its activation by growth factor agonists; only palmitoylated N-Ras becomes GTP-loaded in response to EGF; palmitoylation-deficient N-Ras localizes to endomembranes, fails to be activated by agonists, and cannot sustain EGF- or serum-elicited mitogenic signaling.","method":"Palmitoylation-deficient N-Ras mutants, GTP-loading assay, live-cell Ras-GTP imaging, palmitate content analysis of activated N-Ras, dominant-negative Ras experiments","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — mutagenesis with multiple orthogonal methods (GTP assay, live imaging, palmitate content); single lab","pmids":["23758196"],"is_preprint":false},{"year":2014,"finding":"Wild-type H-Ras or N-Ras downregulation in mutant K-Ras cancer cells leads to hyperactivation of Erk/p90RSK and PI3K/Akt pathways and inhibitory phosphorylation of Chk1 at Ser280, abrogating ATR/Chk1 DNA damage checkpoint activation and sensitizing cells to DNA-damaging chemotherapeutics.","method":"RNAi knockdown, pathway phosphorylation analysis, Chk1 activity assays, chemotherapeutic sensitivity assays in vitro and in vivo","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with specific molecular pathway readout (Chk1 phosphorylation); single lab, multiple methods","pmids":["24525237"],"is_preprint":false},{"year":2015,"finding":"ABHD17 family proteins act as protein depalmitoylases that accelerate palmitate turnover on N-Ras; ABHD17 catalytic activity is required for N-Ras depalmitoylation and relocalization to internal cellular membranes. APT1 and APT2 inhibition (with Palmostatin B) does not affect palmitate turnover on N-Ras, whereas ABHD17 proteins do.","method":"Dual pulse-chase strategy comparing palmitate and protein half-lives, activity profiling, shRNA knockdown, catalytic mutant analysis","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct palmitate turnover assay combined with catalytic mutant analysis and subcellular localization readout; single lab, multiple orthogonal methods","pmids":["26701913"],"is_preprint":false},{"year":2015,"finding":"Singly palmitoylated N-Ras is polarized within the Golgi with relative paucity at the trans-Golgi, in contrast to doubly palmitoylated H-Ras which distributes throughout Golgi stacks; palmitoylation mutants show that degree of acylation controls sub-Golgi distribution.","method":"Confocal live-cell fluorescent imaging, immunogold electron microscopy, palmitoylation mutant analysis","journal":"Journal of cellular physiology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct imaging with two orthogonal methods (confocal + EM) plus mutagenesis; single lab","pmids":["25158650"],"is_preprint":false},{"year":2015,"finding":"Wild-type N-Ras, but not K-Ras, induces IL-8 secretion by binding and activating the cytoplasmic pool of JAK2; IL-8 then acts in autocrine/paracrine fashion on cancer cells and stromal fibroblasts to promote basal-like breast cancer progression.","method":"N-RAS knockdown/overexpression, co-immunoprecipitation of N-Ras with JAK2, cytokine profiling, IL-8 reporter assays, in vivo tumor growth","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP demonstrating N-Ras/JAK2 interaction with isoform specificity (K-Ras negative) and functional downstream readout; single lab","pmids":["26166574"],"is_preprint":false},{"year":2016,"finding":"VPS35, a component of the retromer coat, binds to farnesylated but not palmitoylated N-Ras in the cytosol; this interaction is farnesyl-dependent and GTP-independent. VPS35 silencing increases N-Ras association with cytoplasmic vesicles, diminishes GTP loading of Ras, and inhibits MAPK signaling and growth of N-Ras-dependent melanoma cells.","method":"Affinity purification, mass spectrometry identification, co-immunoprecipitation, farnesyl/palmitoyl mutant analysis, VPS35 siRNA knockdown, subcellular fractionation","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — affinity purification + MS identification + reciprocal co-IP with mutant validation and functional consequence; single lab, multiple orthogonal methods","pmids":["27502489"],"is_preprint":false},{"year":2017,"finding":"N-Ras, H-Ras, and K-Ras show distinct intrinsic GTP hydrolysis rates under identical conditions; the presence of the Raf-RBD further differentiates isoform kinetics; crystal structure of N-Ras bound to a GTP analogue reveals structural features accounting for allosteric isoform-specific differences despite identical active sites.","method":"Enzyme kinetic assays with purified recombinant proteins, crystal structure determination of N-Ras·GTP analogue complex","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted in vitro enzymatic assay combined with crystal structure; single lab but two orthogonal methods (kinetics + structure)","pmids":["28630043"],"is_preprint":false},{"year":2003,"finding":"N-ras proto-oncogene suppresses the malignant phenotype: lack of wild-type N-ras alleles in mice favors thymic lymphoma development, while overexpression of wild-type N-ras protects against lymphomagenesis; introduction of wild-type N-ras into N-ras-deficient tumor cells decreases growth in low serum and soft agar.","method":"N-ras knockout mouse model, transgenic overexpression, in vitro growth assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic in vivo and in vitro loss-of-function/gain-of-function experiments; single lab, multiple model systems","pmids":["12154063"],"is_preprint":false},{"year":2003,"finding":"N-ras is specifically required for normal T-cell function: N-ras knockout mice have reduced CD8 single positive thymocytes, decreased thymocyte proliferation, defective T-cell receptor Ras signaling activation, reduced IL-2 production upon activation, and increased susceptibility to influenza infection.","method":"N-ras knockout mouse model, flow cytometry, thymocyte proliferation assay, Ras signaling/activation assays, in vivo influenza challenge","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knockout with multiple orthogonal phenotypic and molecular readouts, in vitro and in vivo validation; single lab","pmids":["12670913"],"is_preprint":false},{"year":2003,"finding":"Deletion of N-ras rescues a unique subset of developmental defects (skeletal muscle differentiation, MCK gene expression) caused by Rb nullizygosity in mice, and potentiates MyoD transcriptional activity, demonstrating that N-ras and Rb operate in a common pathway controlling differentiation.","method":"Double knockout (Rb−/−; N-ras−/−) mouse model, histological analysis, MCK expression, MyoD transcriptional activity assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in vivo with multiple molecular readouts; establishes pathway relationship between N-ras and Rb","pmids":["12861012"],"is_preprint":false},{"year":2006,"finding":"N-RAS and H-RAS (but not K-RAS) are required for TGF-β1-mediated fibroblast proliferation and ECM synthesis regulation; H-ras−/−/N-ras−/− double knockout fibroblasts show increased ECM synthesis and decreased ERK activation, with compensatory Akt upregulation; MEK/ERK mediates Ras-dependent proliferation while PI3K-Akt mediates ECM synthesis control.","method":"Double knockout (H-ras−/−/N-ras−/−) mouse embryonic fibroblasts, TGF-β1 stimulation, ERK and Akt activation assays, pathway inhibitors, proliferation and ECM assays","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with pathway dissection using inhibitors; single lab, multiple readouts","pmids":["16624289"],"is_preprint":false},{"year":2006,"finding":"Endogenous N-RAS physically interacts with gelsolin; in cells expressing wild-type K-RAS, N-RAS subserves an antiapoptotic role that is compromised by the presence of oncogenic K-RAS; mutant K-RAS elevates GTP-bound N-RAS and alters modulation of the N-RAS:gelsolin complex following apoptotic challenge.","method":"Co-immunoprecipitation of endogenous N-RAS and gelsolin, isogenic cell lines with wild-type vs. mutant K-RAS, apoptosis assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP of endogenous proteins with functional apoptosis readout in isogenic cell lines; single lab","pmids":["17130841"],"is_preprint":false},{"year":2008,"finding":"Galectin-3 N-terminal domain interacts with and inhibits RasGRP4-mediated GTP loading specifically on N-Ras and H-Ras but not K-Ras; EGF-stimulated GTP loading of N-Ras is blocked in high Gal-3-expressing cells; PMA activation of RasGRPs or Gal-3 shRNA knockdown increases N-Ras-GTP levels.","method":"Co-immunoprecipitation, RasGRP4 GEF activity assay on N-Ras, Gal-3 shRNA knockdown, Ras activation assays","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP combined with functional GEF assay and RNAi; single lab, multiple approaches","pmids":["18413234"],"is_preprint":false},{"year":2010,"finding":"TCR-induced activation of endogenous Ras proceeds exclusively at the plasma membrane, not at the Golgi or other endomembranes; palmitoylation of N-Ras is critical for its activation by TCR signals, as palmitoylation-deficient N-Ras confined to endomembranes is not activated.","method":"Live-cell Ras-GTP imaging with novel affinity probes in Jurkat and primary T cells, palmitoylation-deficient Ras mutants, immunological synapse imaging","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — live-cell GTP imaging with palmitoylation mutants and primary cell validation; single lab, multiple orthogonal approaches","pmids":["20713885"],"is_preprint":false},{"year":2011,"finding":"H-ras and N-ras are dispensable for thymocyte development and mature T-cell activation but are critical controllers of Th1 responses: CD4+ T cells from H-ras- or N-ras-deficient mice show markedly decreased IFN-γ production and impaired T-bet induction after TCR stimulation; in vivo Th1 immunity against L. major is defective.","method":"H-ras−/− and N-ras−/− mouse models, T-cell activation assays, cytokine production, T-bet expression, in vivo L. major infection","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knockout with specific molecular pathway readout (T-bet/IFN-γ) validated in vitro and in vivo; single lab, multiple orthogonal approaches","pmids":["21444916"],"is_preprint":false},{"year":2016,"finding":"NRAS(G12V) mutant melanocytes display pronounced PI3K/AKT signaling while NRAS(Q61L) mutant melanocytes display pronounced MAPK signaling; CK2α is significantly overrepresented in NRAS(Q61) mutant cells and these cells are more sensitive to CK2α pharmacologic inhibition.","method":"SILAC-based phosphoproteomics, kinase prediction modeling, pharmacological CK2α inhibition, patient sample validation at mRNA and protein level","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphoproteomic profiling with pharmacological validation; single lab, two orthogonal methods","pmids":["27251789"],"is_preprint":false},{"year":1997,"finding":"Transcription of unr (upstream of N-ras) negatively regulates N-ras expression in vivo through transcriptional interference; deletion of the unr promoter in mice increases N-ras mRNA accumulation by 20–65%.","method":"Homologous recombination deletion of unr promoter in mouse ES cells, RNase protection assays for N-ras mRNA levels","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean genetic deletion with direct mRNA quantification; single lab","pmids":["9450542"],"is_preprint":false}],"current_model":"NRAS encodes a small GTPase that cycles between GDP-bound (inactive) and GTP-bound (active) states; point mutations at codons 12, 13, or 61 reduce intrinsic GTPase activity and lock the protein in its active state, enabling constitutive downstream signaling through Raf/MEK/ERK and PI3K/AKT pathways. Membrane association and signaling competency require sequential prenylation (farnesylation) and palmitoylation: DHHC9·GCP16 palmitoylates N-Ras at the Golgi, directing it to the plasma membrane, while ABHD17 family depalmitoylases remove the palmitate to allow redistribution; VPS35 retromer serves as a cytosolic chaperone for farnesylated, non-palmitoylated N-Ras to regulate its trafficking. N-Ras activation occurs exclusively at the plasma membrane in a palmitoylation-dependent manner, and the membrane itself allosterically controls the conformational states of N-Ras. Compared to K-Ras and H-Ras, N-Ras has distinct intrinsic GTP hydrolysis kinetics determined by allosteric effects, preferentially associates with liquid-disordered lipid domains, and is uniquely activated downstream of plasma membrane Toll-like receptors and TCR signaling; N-Ras uniquely binds and activates cytoplasmic JAK2 to drive IL-8 secretion. Physiologically, N-Ras is required for T-cell function (CD8 thymocyte development, IL-2 production, Th1/IFN-γ responses) and cooperates with pRb in controlling differentiation; its proto-oncogenic form can suppress malignant transformation, whereas activating mutations drive hematopoietic malignancies and melanoma via MAPK reactivation."},"narrative":{"mechanistic_narrative":"NRAS encodes a small GTPase that cycles between GDP- and GTP-bound states and drives proliferation, differentiation, and immune signaling through Raf/MEK/ERK and PI3K/AKT outputs [PMID:6616621, PMID:16624289]. Oncogenic activation arises from point mutations at codons 12, 13, or 61 that reduce intrinsic GTPase activity and lock the protein in its active state; reduced hydrolysis rather than altered nucleotide binding underlies transformation [PMID:6616621, PMID:3550423], and such mutations suppress differentiation programs such as myoblast fusion [PMID:3600660] while driving hematopoietic malignancy and melanoma, including acquired resistance to B-RAF inhibition through MAPK reactivation [PMID:21107323] and STAT3-dependent apoptosis evasion in colorectal tumors [PMID:23274911]. Signaling competency depends on lipid-directed trafficking: N-Ras is farnesylated, or alternatively geranylgeranylated when farnesyltransferase is blocked [PMID:9162087], and is then S-palmitoylated by the Golgi-resident DHHC9·GCP16 complex to target it to the plasma membrane [PMID:16000296, PMID:9335573], where it preferentially partitions into liquid-disordered lipid domains [PMID:16390147] and adopts membrane-controlled signaling conformations [PMID:22203965]. Palmitate is removed by ABHD17-family depalmitoylases to permit redistribution [PMID:26701913], while the VPS35 retromer binds farnesylated, non-palmitoylated N-Ras as a cytosolic chaperone governing trafficking and GTP loading [PMID:27502489]. Activation occurs exclusively at the plasma membrane in a palmitoylation-dependent manner downstream of growth factor receptors, TCR engagement, and plasma-membrane Toll-like receptors [PMID:23758196, PMID:20713885, PMID:21757746]. N-Ras is physiologically required for T-cell function, including CD8 thymocyte development, IL-2 production, and Th1/IFN-γ responses [PMID:12670913, PMID:21444916], and operates in a common differentiation pathway with pRb [PMID:12861012]. Distinct from K-Ras and H-Ras, N-Ras has isoform-specific intrinsic hydrolysis kinetics set by allosteric structural features [PMID:28630043] and uniquely binds and activates cytoplasmic JAK2 to drive IL-8 secretion [PMID:26166574].","teleology":[{"year":1983,"claim":"Established that a single point mutation is sufficient to convert N-ras into an oncogene, defining codon 61 (alongside codon 12) as an activation hotspot.","evidence":"Gene cloning, sequencing, and NIH 3T3 transformation assay","pmids":["6616621"],"confidence":"High","gaps":["Did not define the biochemical defect caused by the mutation","No mechanism linking the mutant to downstream effectors"]},{"year":1985,"claim":"Confirmed across melanoma and rhabdomyosarcoma that codon 61 substitutions alone confer transforming activity, generalizing the activation mechanism beyond a single tumor type.","evidence":"Cloning, sequencing, and transfection/transformation assays in tumor-derived lines","pmids":["3158613","3887133"],"confidence":"High","gaps":["Did not quantify how the mutation alters GTPase function","No downstream pathway readout"]},{"year":1987,"claim":"Pinned the molecular basis of oncogenicity to reduced GTP hydrolysis rather than altered nucleotide binding, and showed oncogenic N-Ras blocks differentiation independent of proliferation.","evidence":"Recombinant mutant proteins with in vitro GTPase/binding assays, microinjection, and differentiation assays in C2 myoblasts","pmids":["3550423","3600660"],"confidence":"High","gaps":["Did not identify the downstream effectors mediating differentiation block","No structural explanation for the GTPase defect"]},{"year":1997,"claim":"Defined how N-Ras achieves membrane association, showing alternative geranylgeranylation under FTI treatment and palmitoylation-dependent kinetic trapping at the plasma membrane.","evidence":"Cell-based prenylation/fractionation under FTI, and lipidated peptide reconstitution with fluorescence microscopy and pharmacological perturbation","pmids":["9162087","9335573"],"confidence":"High","gaps":["Palmitoyltransferase enzyme not yet identified","Did not address how depalmitoylation reverses targeting"]},{"year":1997,"claim":"Identified transcriptional interference from the upstream unr gene as a regulator of N-ras mRNA levels.","evidence":"Homologous recombination deletion of the unr promoter in mice with RNase protection of N-ras mRNA","pmids":["9450542"],"confidence":"Medium","gaps":["Modest effect size (20-65%)","Physiological consequence of altered N-ras levels not tested"]},{"year":1998,"claim":"Demonstrated isoform-selective upstream and downstream coupling, with the hypervariable domain dictating GEF specificity and N-Ras contributing to MAPK output even in H-ras-transformed cells.","evidence":"In vivo GEF selectivity assays, co-IP with Raf-1, and antisense knockdown of c-N-Ras","pmids":["9430727","9525741"],"confidence":"Medium","gaps":["Single-lab co-IP without structural validation","Mechanism of differential GEF engagement at residue level not resolved"]},{"year":1999,"claim":"Showed oncogenic N-Ras remodels the Golgi and cytoskeleton and enhances secretory transport, linking it to organelle physiology beyond canonical signaling.","evidence":"Conditional N-Ras(K61) expression in NRK cells with EM, stereology, transport assays, and PLA2 inhibition","pmids":["9914160"],"confidence":"Medium","gaps":["Effector pathway connecting N-Ras to Golgi collapse unclear","PLA2 inhibitor effect only partial"]},{"year":2001,"claim":"Distinguished N-Ras from K-Ras by negative regulation, showing calmodulin binds and modulates K-Ras but not N-Ras.","evidence":"Calmodulin affinity chromatography and Ras activation assays across isoforms","pmids":["11585916"],"confidence":"Medium","gaps":["Negative result for N-Ras; does not define an N-Ras-specific regulator","Single-lab biochemistry"]},{"year":2003,"claim":"Defined physiological roles of N-ras in tumor suppression, T-cell immunity, and Rb-dependent differentiation through genetic loss-of-function in mice.","evidence":"N-ras knockout, transgenic overexpression, and Rb;N-ras double-knockout mouse models with phenotypic and molecular readouts","pmids":["12154063","12670913","12861012"],"confidence":"High","gaps":["Mechanistic link between N-Ras and the Rb/MyoD axis not biochemically resolved","Compensation by other Ras isoforms not fully excluded"]},{"year":2005,"claim":"Identified the enzyme responsible for N-Ras palmitoylation, establishing DHHC9·GCP16 as a Golgi-localized palmitoyltransferase with substrate specificity for N-Ras and H-Ras.","evidence":"Reconstituted in vitro palmitoyltransferase assay with substrate specificity testing, co-IP, and Golgi localization microscopy","pmids":["16000296"],"confidence":"High","gaps":["Did not define how depalmitoylation is achieved","In vivo requirement for N-Ras signaling not tested in this study"]},{"year":2006,"claim":"Extended N-Ras roles to TGF-β-driven fibroblast biology and revealed gelsolin as a physical partner mediating an antiapoptotic function modulated by K-Ras status.","evidence":"H-ras/N-ras double-knockout fibroblasts with pathway dissection, and co-IP of endogenous N-Ras with gelsolin in isogenic K-RAS lines","pmids":["16624289","17130841"],"confidence":"Medium","gaps":["Single-lab co-IP for the gelsolin interaction","Direct contribution of gelsolin binding to apoptosis resistance not isolated"]},{"year":2006,"claim":"Provided biophysical basis for membrane preference, showing lipidated N-Ras favors liquid-disordered domains and phase boundaries.","evidence":"Two-photon fluorescence microscopy and AFM on giant unilamellar vesicles with fully lipidated N-Ras","pmids":["16390147"],"confidence":"High","gaps":["Reconstituted model system; in-cell phase behavior not directly shown","Functional consequence of domain preference for signaling not addressed here"]},{"year":2008,"claim":"Identified galectin-3 as an isoform-selective negative regulator of N-Ras/H-Ras activation by inhibiting RasGRP4-mediated GTP loading.","evidence":"Co-IP, RasGRP4 GEF activity assays, and Gal-3 shRNA knockdown with Ras activation readouts","pmids":["18413234"],"confidence":"Medium","gaps":["Single-lab mechanism","Structural basis of selective inhibition not resolved"]},{"year":2009,"claim":"Linked Rb loss to N-Ras activation via E2F-driven prenyltransferase upregulation, coupling N-Ras hyperactivity to senescence and DNA damage response.","evidence":"Rb-heterozygous mouse model with E2F target analysis, N-Ras activity assays, and senescence readouts","pmids":["19345325"],"confidence":"Medium","gaps":["Causal sufficiency of prenylation increase not fully isolated","Single-model system"]},{"year":2010,"claim":"Demonstrated activation occurs exclusively at the plasma membrane in a palmitoylation-dependent manner downstream of TCR signaling.","evidence":"Live-cell Ras-GTP imaging with affinity probes and palmitoylation-deficient mutants in Jurkat and primary T cells","pmids":["20713885"],"confidence":"High","gaps":["GEF responsible for plasma-membrane activation not identified","Did not resolve spatial dynamics relative to the synapse at molecular detail"]},{"year":2010,"claim":"Established N-RAS mutation as a clinically relevant mechanism of acquired B-RAF inhibitor resistance through MAPK reactivation.","evidence":"Resistant cell derivation, N-RAS knockdown and Q61K overexpression with MAPK readouts, validated in patient biopsies","pmids":["21107323"],"confidence":"High","gaps":["Did not address combination strategies to overcome resistance","Other resistance routes not excluded"]},{"year":2011,"claim":"Connected plasma-membrane Toll-like receptor signaling to selective N-Ras activation driving IL-6 secretion and proliferation via a TRAF6-independent route.","evidence":"Isoform-selective Ras activation assays, RNAi of N-Ras and TRAF6, and IL-6 reporter/proliferation assays in cholangiocytes","pmids":["21757746"],"confidence":"Medium","gaps":["The adaptor coupling TLRs to N-Ras unidentified","Single cell-type context"]},{"year":2011,"claim":"Showed the membrane is an active conformational partner that, with depalmitoylation and raft clustering, governs N-Ras conformation and plasma-membrane-to-cytoplasm exchange.","evidence":"Pressure-FTIR conformational analysis and patch-FRAP/EM with palmitoylation-deficient mutants and cholesterol depletion","pmids":["22203965","21807892"],"confidence":"Medium","gaps":["FTIR conformer assignments lack mutagenesis follow-up","Single-lab biophysical methods"]},{"year":2012,"claim":"Defined a noncanonical mutant N-RAS survival pathway through STAT3, identifying MEK inhibition as a selective vulnerability in mutant-N-RAS colorectal tumors.","evidence":"Genetically engineered mouse model with STAT3 pathway analysis, MEK inhibition, and apoptosis assays","pmids":["23274911"],"confidence":"High","gaps":["Direct molecular link from N-RAS to STAT3 not fully mapped","Generality beyond colorectal context untested here"]},{"year":2013,"claim":"Established palmitoylation as a strict requirement for agonist-driven N-Ras GTP loading and sustained mitogenic signaling.","evidence":"Palmitoylation-deficient mutants with GTP-loading assays, live-cell imaging, and palmitate content analysis of activated N-Ras","pmids":["23758196"],"confidence":"High","gaps":["Did not identify the depalmitoylase governing the cycle","Spatial coordination with the palmitoyltransferase not resolved"]},{"year":2014,"claim":"Revealed a tumor-suppressive function of wild-type N-Ras/H-Ras in mutant-K-Ras cells, maintaining the ATR/Chk1 DNA damage checkpoint.","evidence":"RNAi knockdown with pathway phosphorylation analysis and chemosensitivity assays in vitro and in vivo","pmids":["24525237"],"confidence":"Medium","gaps":["Mechanism connecting wild-type Ras to Chk1 Ser280 phosphorylation indirect","Single-lab study"]},{"year":2015,"claim":"Resolved the depalmitoylation arm of the trafficking cycle, identifying ABHD17 (not APT1/2) as the depalmitoylase driving N-Ras palmitate turnover and relocalization, and refined sub-Golgi distribution by acylation degree.","evidence":"Pulse-chase palmitate/protein half-life comparison, catalytic mutants, shRNA, and confocal/EM imaging of palmitoylation mutants","pmids":["26701913","25158650"],"confidence":"High","gaps":["How ABHD17 is targeted to N-Ras pools not defined","Coupling of depalmitoylation kinetics to signaling output not quantified"]},{"year":2015,"claim":"Identified a unique, isoform-specific effector function in which wild-type N-Ras binds and activates cytoplasmic JAK2 to drive IL-8 secretion and tumor progression.","evidence":"N-RAS knockdown/overexpression, N-Ras·JAK2 co-IP, cytokine profiling, and in vivo tumor growth","pmids":["26166574"],"confidence":"Medium","gaps":["Single-lab co-IP; direct binding interface not defined","Dependence on GTP state and membrane context untested"]},{"year":2016,"claim":"Linked specific N-RAS mutation classes to divergent signaling outputs and a CK2α vulnerability in codon-61 mutant melanoma.","evidence":"SILAC phosphoproteomics, kinase prediction, pharmacological CK2α inhibition, and patient sample validation","pmids":["27251789"],"confidence":"Medium","gaps":["Mechanism by which Q61 versus G12 mutations bias pathway choice unresolved","Single-lab profiling"]},{"year":2016,"claim":"Identified VPS35/retromer as a cytosolic chaperone for farnesylated, non-palmitoylated N-Ras required for its GTP loading and oncogenic signaling.","evidence":"Affinity purification/MS, reciprocal co-IP with farnesyl/palmitoyl mutants, VPS35 silencing, and fractionation in melanoma cells","pmids":["27502489"],"confidence":"High","gaps":["How VPS35 hands off N-Ras to the palmitoylation machinery not defined","Structural basis of farnesyl recognition unknown"]},{"year":2017,"claim":"Provided the structural and kinetic basis for isoform-specific behavior, showing N-Ras has distinct intrinsic hydrolysis kinetics set by allosteric features despite an identical active site.","evidence":"Enzyme kinetics with purified recombinant Ras isoforms and crystal structure of N-Ras bound to a GTP analogue","pmids":["28630043"],"confidence":"High","gaps":["Allosteric residues responsible not functionally validated by mutagenesis","In-cell relevance of kinetic differences not directly tested"]},{"year":null,"claim":"It remains unresolved how the spatial palmitoylation/depalmitoylation cycle, VPS35 chaperoning, and membrane-controlled conformations are integrated to dictate which effector arm (Raf/MEK/ERK, PI3K/AKT, JAK2, or STAT3) a given N-Ras mutant engages in a specific cellular context.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified spatiotemporal model linking trafficking machinery to effector selection","GEFs activating N-Ras at the plasma membrane downstream of TCR/TLR not identified","Mutation-class-specific effector bias mechanism unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003924","term_label":"GTPase activity","supporting_discovery_ids":[3,25]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,19,32]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[6,12]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[6,19,32]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[11,22]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[24]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,14,19]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[14,18]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[27,33,32]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,28]}],"complexes":["VPS35/retromer (as bound cargo)"],"partners":["RAF1","JAK2","VPS35","GSN","LGALS3","DHHC9","GCP16","ABHD17"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P01111","full_name":"GTPase NRas","aliases":["Transforming protein N-Ras"],"length_aa":189,"mass_kda":21.2,"function":"Ras proteins bind GDP/GTP and possess intrinsic GTPase activity","subcellular_location":"Cell membrane; Golgi apparatus membrane","url":"https://www.uniprot.org/uniprotkb/P01111/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NRAS","classification":"Not Classified","n_dependent_lines":103,"n_total_lines":1208,"dependency_fraction":0.08526490066225166},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CD9","stoichiometry":0.2},{"gene":"SLC16A1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/NRAS","total_profiled":1310},"omim":[{"mim_id":"621092","title":"IQ MOTIF-CONTAINING GTPase-ACTIVATING PROTEIN 3; IQGAP3","url":"https://www.omim.org/entry/621092"},{"mim_id":"620963","title":"ZDHHC PALMITOYLTRANSFERASE 18; ZDHHC18","url":"https://www.omim.org/entry/620963"},{"mim_id":"619767","title":"PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE SYNDROME, TELOMERE-RELATED, 6; PFBMFT6","url":"https://www.omim.org/entry/619767"},{"mim_id":"618499","title":"NOONAN SYNDROME 11; NS11","url":"https://www.omim.org/entry/618499"},{"mim_id":"617944","title":"ABHYDROLASE DOMAIN-CONTAINING PROTEIN 17C, DEPALMITOYLASE; ABHD17C","url":"https://www.omim.org/entry/617944"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/NRAS"},"hgnc":{"alias_symbol":["N-ras"],"prev_symbol":[]},"alphafold":{"accession":"P01111","domains":[{"cath_id":"3.40.50.300","chopping":"1-175","consensus_level":"high","plddt":95.0897,"start":1,"end":175}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P01111","model_url":"https://alphafold.ebi.ac.uk/files/AF-P01111-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P01111-F1-predicted_aligned_error_v6.png","plddt_mean":92.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NRAS","jax_strain_url":"https://www.jax.org/strain/search?query=NRAS"},"sequence":{"accession":"P01111","fasta_url":"https://rest.uniprot.org/uniprotkb/P01111.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P01111/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P01111"}},"corpus_meta":[{"pmid":"21107323","id":"PMC_21107323","title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21107323","citation_count":1759,"is_preprint":false},{"pmid":"9162087","id":"PMC_9162087","title":"K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9162087","citation_count":751,"is_preprint":false},{"pmid":"6616621","id":"PMC_6616621","title":"Structure and activation of the human N-ras gene.","date":"1983","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/6616621","citation_count":534,"is_preprint":false},{"pmid":"9334313","id":"PMC_9334313","title":"K-ras is an essential gene in the mouse with partial functional overlap with N-ras.","date":"1997","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9334313","citation_count":462,"is_preprint":false},{"pmid":"16000296","id":"PMC_16000296","title":"DHHC9 and GCP16 constitute a human protein fatty acyltransferase with specificity for H- and N-Ras.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16000296","citation_count":290,"is_preprint":false},{"pmid":"26701913","id":"PMC_26701913","title":"ABHD17 proteins are novel protein depalmitoylases that regulate N-Ras palmitate turnover and subcellular localization.","date":"2015","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/26701913","citation_count":283,"is_preprint":false},{"pmid":"3103719","id":"PMC_3103719","title":"Mutations in N-ras predominate in acute myeloid leukemia.","date":"1987","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/3103719","citation_count":255,"is_preprint":false},{"pmid":"3295562","id":"PMC_3295562","title":"A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome.","date":"1987","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/3295562","citation_count":237,"is_preprint":false},{"pmid":"3600660","id":"PMC_3600660","title":"The oncogenic forms of N-ras or H-ras prevent skeletal myoblast differentiation.","date":"1987","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3600660","citation_count":218,"is_preprint":false},{"pmid":"7878045","id":"PMC_7878045","title":"The murine N-ras gene is not essential for growth and development.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7878045","citation_count":204,"is_preprint":false},{"pmid":"12873990","id":"PMC_12873990","title":"Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12873990","citation_count":176,"is_preprint":false},{"pmid":"11585916","id":"PMC_11585916","title":"Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11585916","citation_count":159,"is_preprint":false},{"pmid":"2200539","id":"PMC_2200539","title":"N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance.","date":"1990","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/2200539","citation_count":147,"is_preprint":false},{"pmid":"3285909","id":"PMC_3285909","title":"Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes.","date":"1988","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/3285909","citation_count":136,"is_preprint":false},{"pmid":"24980823","id":"PMC_24980823","title":"MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24980823","citation_count":126,"is_preprint":false},{"pmid":"2991860","id":"PMC_2991860","title":"Human N-ras: cDNA cloning and gene structure.","date":"1985","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/2991860","citation_count":125,"is_preprint":false},{"pmid":"24525237","id":"PMC_24525237","title":"Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.","date":"2014","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/24525237","citation_count":122,"is_preprint":false},{"pmid":"34098219","id":"PMC_34098219","title":"NRAS mutant melanoma: Towards better therapies.","date":"2021","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/34098219","citation_count":121,"is_preprint":false},{"pmid":"2105496","id":"PMC_2105496","title":"Characterization of c-Ki-ras and N-ras oncogenes in aflatoxin B1-induced rat liver tumors.","date":"1990","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2105496","citation_count":121,"is_preprint":false},{"pmid":"14737077","id":"PMC_14737077","title":"Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.","date":"2004","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/14737077","citation_count":120,"is_preprint":false},{"pmid":"8161790","id":"PMC_8161790","title":"Mutations of the N-ras gene in juvenile chronic myelogenous leukemia.","date":"1994","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8161790","citation_count":118,"is_preprint":false},{"pmid":"24861879","id":"PMC_24861879","title":"MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.","date":"2014","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24861879","citation_count":118,"is_preprint":false},{"pmid":"9335573","id":"PMC_9335573","title":"S-Acylation and plasma membrane targeting of the farnesylated carboxyl-terminal peptide of N-ras in mammalian fibroblasts.","date":"1997","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9335573","citation_count":114,"is_preprint":false},{"pmid":"28630043","id":"PMC_28630043","title":"The small GTPases K-Ras, N-Ras, and H-Ras have distinct biochemical properties determined by allosteric effects.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28630043","citation_count":109,"is_preprint":false},{"pmid":"19345325","id":"PMC_19345325","title":"Rb Regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation.","date":"2009","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/19345325","citation_count":105,"is_preprint":false},{"pmid":"10465111","id":"PMC_10465111","title":"Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi.","date":"1999","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10465111","citation_count":101,"is_preprint":false},{"pmid":"16390147","id":"PMC_16390147","title":"Visualizing association of N-ras in lipid microdomains: influence of domain structure and interfacial adsorption.","date":"2006","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/16390147","citation_count":98,"is_preprint":false},{"pmid":"6672765","id":"PMC_6672765","title":"Regional chromosomal localization of N-ras, K-ras-1, K-ras-2 and myb oncogenes in human cells.","date":"1983","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/6672765","citation_count":97,"is_preprint":false},{"pmid":"3550423","id":"PMC_3550423","title":"Biochemical and biological properties of the human N-ras p21 protein.","date":"1987","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3550423","citation_count":95,"is_preprint":false},{"pmid":"10068678","id":"PMC_10068678","title":"Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice.","date":"1999","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10068678","citation_count":94,"is_preprint":false},{"pmid":"3887133","id":"PMC_3887133","title":"Activation of N-ras in a human melanoma cell line.","date":"1985","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3887133","citation_count":91,"is_preprint":false},{"pmid":"22203965","id":"PMC_22203965","title":"Revealing conformational substates of lipidated N-Ras protein by pressure modulation.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22203965","citation_count":90,"is_preprint":false},{"pmid":"9430727","id":"PMC_9430727","title":"Ras-GRF activates Ha-Ras, but not N-Ras or K-Ras 4B, protein in vivo.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9430727","citation_count":84,"is_preprint":false},{"pmid":"16103080","id":"PMC_16103080","title":"Galectin-3 regulates a molecular switch from N-Ras to K-Ras usage in human breast carcinoma cells.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16103080","citation_count":84,"is_preprint":false},{"pmid":"8043423","id":"PMC_8043423","title":"Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi.","date":"1994","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/8043423","citation_count":83,"is_preprint":false},{"pmid":"15737846","id":"PMC_15737846","title":"Detection of B-RAF and N-RAS mutations in human melanoma.","date":"2005","source":"Journal of the American College of Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/15737846","citation_count":76,"is_preprint":false},{"pmid":"20145188","id":"PMC_20145188","title":"Elevated phosphate activates N-ras and promotes cell transformation and skin tumorigenesis.","date":"2010","source":"Cancer prevention research (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/20145188","citation_count":72,"is_preprint":false},{"pmid":"16404744","id":"PMC_16404744","title":"K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements.","date":"2006","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16404744","citation_count":72,"is_preprint":false},{"pmid":"3856429","id":"PMC_3856429","title":"Human c-myc and N-ras expression during induction of HL-60 cellular differentiation.","date":"1985","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/3856429","citation_count":69,"is_preprint":false},{"pmid":"6582353","id":"PMC_6582353","title":"Activation of N-ras gene in bone marrow cells from a patient with acute myeloblastic leukaemia.","date":"1984","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/6582353","citation_count":68,"is_preprint":false},{"pmid":"24588908","id":"PMC_24588908","title":"MEK targeting in N-RAS mutated metastatic melanoma.","date":"2014","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24588908","citation_count":63,"is_preprint":false},{"pmid":"31398831","id":"PMC_31398831","title":"Atypical BRAF and NRAS Mutations in Mucosal Melanoma.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31398831","citation_count":62,"is_preprint":false},{"pmid":"9525741","id":"PMC_9525741","title":"Ha-ras and N-ras regulate MAPK activity by distinct mechanisms in vivo.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9525741","citation_count":62,"is_preprint":false},{"pmid":"3275590","id":"PMC_3275590","title":"Mutation analysis of the N-ras proto-oncogene in active and remission phase of human acute leukemias.","date":"1988","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/3275590","citation_count":61,"is_preprint":false},{"pmid":"1617670","id":"PMC_1617670","title":"N-ras mutation in ultraviolet radiation-induced murine skin cancers.","date":"1992","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/1617670","citation_count":60,"is_preprint":false},{"pmid":"3011151","id":"PMC_3011151","title":"Absence of oncogene amplifications and occasional activation of N-ras in lymphoblastic leukemia of childhood.","date":"1986","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/3011151","citation_count":59,"is_preprint":false},{"pmid":"21757746","id":"PMC_21757746","title":"Cholangiocyte N-Ras protein mediates lipopolysaccharide-induced interleukin 6 secretion and proliferation.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21757746","citation_count":56,"is_preprint":false},{"pmid":"2204029","id":"PMC_2204029","title":"Characterization of unr; a gene closely linked to N-ras.","date":"1990","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/2204029","citation_count":56,"is_preprint":false},{"pmid":"1574246","id":"PMC_1574246","title":"Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia.","date":"1992","source":"Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/1574246","citation_count":56,"is_preprint":false},{"pmid":"8057669","id":"PMC_8057669","title":"N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome.","date":"1994","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/8057669","citation_count":55,"is_preprint":false},{"pmid":"22453013","id":"PMC_22453013","title":"Targeting NRAS in melanoma.","date":"2012","source":"Cancer journal (Sudbury, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/22453013","citation_count":54,"is_preprint":false},{"pmid":"10698496","id":"PMC_10698496","title":"H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10698496","citation_count":54,"is_preprint":false},{"pmid":"8947520","id":"PMC_8947520","title":"Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors.","date":"1996","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/8947520","citation_count":52,"is_preprint":false},{"pmid":"11727262","id":"PMC_11727262","title":"H-, K-, and N-ras gene mutation in atypical fibroxanthoma and malignant fibrous histiocytoma.","date":"2001","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11727262","citation_count":50,"is_preprint":false},{"pmid":"23274911","id":"PMC_23274911","title":"Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression.","date":"2012","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/23274911","citation_count":50,"is_preprint":false},{"pmid":"1549347","id":"PMC_1549347","title":"Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia.","date":"1992","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/1549347","citation_count":49,"is_preprint":false},{"pmid":"22758774","id":"PMC_22758774","title":"GNA11 and N-RAS mutations: alternatives for MAPK pathway activating GNAQ mutations in primary melanocytic tumours of the central nervous system.","date":"2013","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/22758774","citation_count":49,"is_preprint":false},{"pmid":"12154063","id":"PMC_12154063","title":"The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene.","date":"2002","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12154063","citation_count":49,"is_preprint":false},{"pmid":"29038336","id":"PMC_29038336","title":"The K-Ras, N-Ras, and H-Ras Isoforms: Unique Conformational Preferences and Implications for Targeting Oncogenic Mutants.","date":"2018","source":"Cold Spring Harbor perspectives in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29038336","citation_count":48,"is_preprint":false},{"pmid":"12670913","id":"PMC_12670913","title":"Mice deficient for N-ras: impaired antiviral immune response and T-cell function.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12670913","citation_count":48,"is_preprint":false},{"pmid":"10958945","id":"PMC_10958945","title":"H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers.","date":"2000","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/10958945","citation_count":48,"is_preprint":false},{"pmid":"27502489","id":"PMC_27502489","title":"VPS35 binds farnesylated N-Ras in the cytosol to regulate N-Ras trafficking.","date":"2016","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27502489","citation_count":47,"is_preprint":false},{"pmid":"2676145","id":"PMC_2676145","title":"Activated N-ras oncogenes in human neuroblastoma.","date":"1989","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/2676145","citation_count":47,"is_preprint":false},{"pmid":"25158650","id":"PMC_25158650","title":"The differential palmitoylation states of N-Ras and H-Ras determine their distinct Golgi subcompartment localizations.","date":"2015","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25158650","citation_count":46,"is_preprint":false},{"pmid":"9450542","id":"PMC_9450542","title":"Transcription of unr (upstream of N-ras) down-modulates N-ras expression in vivo.","date":"1997","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9450542","citation_count":46,"is_preprint":false},{"pmid":"2992777","id":"PMC_2992777","title":"Tumorigenicity and transcriptional modulation of c-myc and N-ras oncogenes in a human hepatoma cell line.","date":"1985","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/2992777","citation_count":46,"is_preprint":false},{"pmid":"12861012","id":"PMC_12861012","title":"Rb and N-ras function together to control differentiation in the mouse.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12861012","citation_count":45,"is_preprint":false},{"pmid":"26166574","id":"PMC_26166574","title":"Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation.","date":"2015","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26166574","citation_count":45,"is_preprint":false},{"pmid":"2457379","id":"PMC_2457379","title":"Evaluation of N-ras oncogene anti-sense, sense and nonsense sequence methylphosphonate oligonucleotide analogues.","date":"1988","source":"Anti-cancer drug design","url":"https://pubmed.ncbi.nlm.nih.gov/2457379","citation_count":44,"is_preprint":false},{"pmid":"3060800","id":"PMC_3060800","title":"Activation of N-ras induced by ultraviolet irradiation in vitro.","date":"1988","source":"Oncogene research","url":"https://pubmed.ncbi.nlm.nih.gov/3060800","citation_count":44,"is_preprint":false},{"pmid":"16624289","id":"PMC_16624289","title":"Involvement of H- and N-Ras isoforms in transforming growth factor-beta1-induced proliferation and in collagen and fibronectin synthesis.","date":"2006","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/16624289","citation_count":44,"is_preprint":false},{"pmid":"3158613","id":"PMC_3158613","title":"N-ras gene activation in the RD human rhabdomyosarcoma cell line.","date":"1985","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/3158613","citation_count":43,"is_preprint":false},{"pmid":"21807892","id":"PMC_21807892","title":"Raft protein clustering alters N-Ras membrane interactions and activation pattern.","date":"2011","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21807892","citation_count":40,"is_preprint":false},{"pmid":"2247846","id":"PMC_2247846","title":"N-ras 61 oncogene mutations in Hürthle cell tumors.","date":"1990","source":"Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/2247846","citation_count":40,"is_preprint":false},{"pmid":"30571927","id":"PMC_30571927","title":"Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gαq and Gα11 and kill uveal melanoma cells.","date":"2018","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30571927","citation_count":39,"is_preprint":false},{"pmid":"9695411","id":"PMC_9695411","title":"Mutational analysis of the N-ras gene in acute lymphoblastic leukemia: a study of 125 Japanese pediatric cases.","date":"1998","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/9695411","citation_count":38,"is_preprint":false},{"pmid":"21444916","id":"PMC_21444916","title":"H-ras and N-ras are dispensable for T-cell development and activation but critical for protective Th1 immunity.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21444916","citation_count":37,"is_preprint":false},{"pmid":"24811402","id":"PMC_24811402","title":"MiR-214 and N-ras regulatory loop suppresses rhabdomyosarcoma cell growth and xenograft tumorigenesis.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24811402","citation_count":34,"is_preprint":false},{"pmid":"7704243","id":"PMC_7704243","title":"N-ras mutation of thyroid tumor with special reference to the follicular type.","date":"1995","source":"Pathology international","url":"https://pubmed.ncbi.nlm.nih.gov/7704243","citation_count":34,"is_preprint":false},{"pmid":"20713885","id":"PMC_20713885","title":"TCR-induced activation of Ras proceeds at the plasma membrane and requires palmitoylation of N-Ras.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20713885","citation_count":33,"is_preprint":false},{"pmid":"1544704","id":"PMC_1544704","title":"N-ras gene mutations in acute myeloid leukemia: accurate detection by solid-phase minisequencing.","date":"1992","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/1544704","citation_count":32,"is_preprint":false},{"pmid":"14558822","id":"PMC_14558822","title":"Synthesis and biological activity of photoactivatable N-ras peptides and proteins.","date":"2003","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/14558822","citation_count":32,"is_preprint":false},{"pmid":"7987834","id":"PMC_7987834","title":"An overexpressed N-ras proto-oncogene cooperates with N-methylnitrosourea in mouse mammary carcinogenesis.","date":"1994","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7987834","citation_count":31,"is_preprint":false},{"pmid":"8806695","id":"PMC_8806695","title":"Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis.","date":"1996","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8806695","citation_count":30,"is_preprint":false},{"pmid":"14984964","id":"PMC_14984964","title":"Transcriptional activation of H- and N-ras oncogenes in human cervical cancer.","date":"2004","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/14984964","citation_count":29,"is_preprint":false},{"pmid":"18461565","id":"PMC_18461565","title":"N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells.","date":"2008","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18461565","citation_count":28,"is_preprint":false},{"pmid":"17130841","id":"PMC_17130841","title":"Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS:gelsolin complex.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17130841","citation_count":28,"is_preprint":false},{"pmid":"29219657","id":"PMC_29219657","title":"The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.","date":"2017","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29219657","citation_count":28,"is_preprint":false},{"pmid":"9914160","id":"PMC_9914160","title":"N-Ras induces alterations in Golgi complex architecture and in constitutive protein transport.","date":"1999","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/9914160","citation_count":27,"is_preprint":false},{"pmid":"25537506","id":"PMC_25537506","title":"SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25537506","citation_count":26,"is_preprint":false},{"pmid":"25788415","id":"PMC_25788415","title":"Activated k-ras, but not h-ras or N-ras, regulates brain neural stem cell proliferation in a raf/rb-dependent manner.","date":"2015","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/25788415","citation_count":26,"is_preprint":false},{"pmid":"7750091","id":"PMC_7750091","title":"N-ras mutation in 7,12-dimethylbenz[a]anthracene (DMBA)-induced erythroleukemia in Long-Evans rats.","date":"1995","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/7750091","citation_count":26,"is_preprint":false},{"pmid":"1967219","id":"PMC_1967219","title":"Alteration of N-ras gene mutation after relapse in acute lymphoblastic leukemia.","date":"1990","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/1967219","citation_count":25,"is_preprint":false},{"pmid":"19563783","id":"PMC_19563783","title":"Dual knockdown of N-ras and epiregulin synergistically suppressed the growth of human hepatoma cells.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19563783","citation_count":25,"is_preprint":false},{"pmid":"32697992","id":"PMC_32697992","title":"Pseudo-RNA-Binding Domains Mediate RNA Structure Specificity in Upstream of N-Ras.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32697992","citation_count":24,"is_preprint":false},{"pmid":"18668139","id":"PMC_18668139","title":"Active N-Ras and B-Raf inhibit anoikis by downregulating Bim expression in melanocytic cells.","date":"2008","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/18668139","citation_count":24,"is_preprint":false},{"pmid":"23758196","id":"PMC_23758196","title":"Ras palmitoylation is necessary for N-Ras activation and signal propagation in growth factor signalling.","date":"2013","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/23758196","citation_count":23,"is_preprint":false},{"pmid":"28426398","id":"PMC_28426398","title":"K-RAS and N-RAS mutations in testicular germ cell tumors.","date":"2017","source":"Bosnian journal of basic medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28426398","citation_count":22,"is_preprint":false},{"pmid":"27251789","id":"PMC_27251789","title":"Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.","date":"2016","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/27251789","citation_count":22,"is_preprint":false},{"pmid":"18413234","id":"PMC_18413234","title":"Galectin-3 regulates RasGRP4-mediated activation of N-Ras and H-Ras.","date":"2008","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/18413234","citation_count":21,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47326,"output_tokens":8868,"usd":0.137499,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18750,"output_tokens":7126,"usd":0.13595,"stage2_stop_reason":"end_turn"},"total_usd":0.273449,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1983,\n      \"finding\": \"A single nucleotide change at codon 61 of N-ras (glutamine to lysine substitution) activates its transforming potential, establishing that point mutations at codon 61 (and previously identified codon 12) are sufficient for oncogenic activation.\",\n      \"method\": \"Gene cloning, DNA sequencing, NIH 3T3 transformation assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct sequencing plus functional transformation assay, foundational paper replicated across many subsequent studies\",\n      \"pmids\": [\"6616621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"Oncogenic N-ras (codon 61, glutamine to histidine) was cloned from a rhabdomyosarcoma cell line; a mutation at position 61 (CAA to CAT) is sufficient for transforming activity, confirming codon 61 as a key activation site.\",\n      \"method\": \"Gene cloning, chimeric recombinant construction, DNA sequencing, NIH 3T3 transformation assay\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — functional transformation assay combined with sequencing; replicates the codon 61 finding from multiple labs\",\n      \"pmids\": [\"3158613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"Activation of N-ras in melanoma cells involves a codon 61 mutation (glutamine to lysine), and only clones carrying this mutation are biologically active in transfection assays.\",\n      \"method\": \"Southern blot, oligonucleotide hybridization, DNA sequencing, transfection/transformation assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct sequencing plus functional transformation assay, replicated across labs\",\n      \"pmids\": [\"3887133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"Normal and mutant (Gly-12, Asp-12, Val-12) human N-ras p21 proteins were produced in E. coli; mutant proteins showed reduced GTPase activity (Val-12 retains 12%, Asp-12 retains 43% of wild-type) while both were equally potent in inducing morphological transformation, indicating reduced GTPase rather than altered nucleotide binding drives oncogenicity.\",\n      \"method\": \"Recombinant protein production in E. coli, GTPase activity assay, guanine nucleotide binding assay, microinjection into NIH 3T3 cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted in vitro enzymatic assay with mutagenesis and functional cellular readout\",\n      \"pmids\": [\"3550423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"Oncogenic forms of N-ras (but not the proto-oncogenic form) completely suppress skeletal myoblast differentiation (fusion, muscle-specific gene expression including nicotinic acetylcholine receptor and creatine kinase) in C2 cells at the level of mRNA accumulation, independently of effects on cell proliferation.\",\n      \"method\": \"DNA-mediated gene transfer into mouse C2 skeletal muscle cells, analysis of muscle-specific mRNA and protein markers\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean gain-of-function with defined molecular readout; proto-oncogene vs oncogene comparison as internal control\",\n      \"pmids\": [\"3600660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"In the presence of farnesyl protein transferase inhibitors, N-Ras (unlike H-Ras) is alternatively prenylated by geranylgeranyl transferase-1 and remains associated with the membrane fraction, explaining why FTIs fail to displace N-Ras from membranes.\",\n      \"method\": \"Cell-based prenylation assay in COS cells and DLD-1 colon carcinoma cells; membrane fractionation; FTI treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct biochemical fractionation with isoform-by-isoform comparison, replicated in two cell systems\",\n      \"pmids\": [\"9162087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"S-palmitoylation of the farnesylated C-terminal peptide of N-ras stabilizes membrane association and mediates plasma membrane targeting; the S-acylated form localizes preferentially to the plasma membrane in CV-1 cells, and this localization is maintained by a 'kinetic trapping' mechanism at the plasma membrane itself, not through the secretory pathway.\",\n      \"method\": \"Fluorescent lipid-modified peptide reconstitution with liposomes, cell culture uptake assay, fluorescence microscopy, brefeldin A and low-temperature treatments\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted peptide system with orthogonal fluorescence microscopy and pharmacological perturbation; single lab\",\n      \"pmids\": [\"9335573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Ras-GRF/Cdc25Mm selectively activates Ha-Ras but not N-Ras or K-Ras 4B in vivo; the C-terminal hypervariable domain of Ras proteins dictates this GEF specificity, indicating that Ras isoforms can engage distinct upstream activators.\",\n      \"method\": \"In vivo Ras activation assay in cells, GEF selectivity assay, C-terminal domain analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single lab, single method demonstrating differential GEF activation; domain mapping provides partial mechanistic support\",\n      \"pmids\": [\"9430727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"In Ha-ras-transformed fibroblasts, Raf-1 co-immunoprecipitates with endogenous c-N-Ras but not with (G12V)Ha-Ras, suggesting N-Ras has higher affinity for Raf-1 than Ha-Ras in vivo; antisense knockdown of c-N-Ras abrogates constitutive MAPK activity of Ha-ras-transformed cells, demonstrating that c-N-Ras function is required for Ha-Ras-driven MAPK signaling.\",\n      \"method\": \"Co-immunoprecipitation, antisense oligonucleotide knockdown, MAPK activity assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP combined with functional knockdown; single lab, two orthogonal approaches\",\n      \"pmids\": [\"9525741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Transforming N-Ras(K61) mutant expression in NRK cells causes fragmentation and collapse of the Golgi complex, disruption of the actin cytoskeleton, and increased constitutive protein transport from the trans-Golgi network to the cell surface; these effects are partially inhibited by a phospholipase A2 inhibitor.\",\n      \"method\": \"Conditional expression system, electron microscopy, stereological analysis, protein transport assay, pharmacological inhibition\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional expression with ultrastructural and functional readouts; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"9914160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Calmodulin binds to K-Ras but not to N-Ras or H-Ras, as demonstrated by calmodulin affinity chromatography; calmodulin inhibition preferentially activates K-Ras, not N-Ras.\",\n      \"method\": \"Calmodulin affinity chromatography from cellular lysates, Ras activation assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct affinity chromatography with isoform comparison; negative result for N-Ras binding is mechanistically informative; single lab\",\n      \"pmids\": [\"11585916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"DHHC9 and GCP16 form a protein complex that functions as a human protein palmitoyltransferase with substrate specificity for H-Ras and N-Ras but not for myristoylated Gαi1 or GAP-43; DHHC9 requires GCP16 for enzymatic activity and protein stability; the complex co-distributes in the Golgi apparatus.\",\n      \"method\": \"Purified DHHC9·GCP16 complex palmitoyltransferase assay in vitro, co-immunoprecipitation, subcellular localization by microscopy\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted in vitro palmitoyltransferase assay with substrate specificity determination plus co-IP and localization; functional analog validated against yeast ortholog\",\n      \"pmids\": [\"16000296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"N-Ras lipidated protein partitions preferentially into liquid-disordered (ld) lipid domains rather than liquid-ordered (lo) or solid-ordered (so) domains, with the phase preference order ld > lo >> so; additionally, a large proportion localizes at the ld/lo phase boundary, suggesting an interfacial adsorption mechanism.\",\n      \"method\": \"Two-photon fluorescence microscopy on giant unilamellar vesicles, tapping-mode atomic force microscopy with fully lipidated (hexadecylated and farnesylated) fluorescent N-Ras protein\",\n      \"journal\": \"Journal of the American Chemical Society\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted fully lipidated protein with two independent orthogonal biophysical methods (fluorescence microscopy + AFM); single lab\",\n      \"pmids\": [\"16390147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"pRb inactivation induces E2F-dependent upregulation of farnesyl diphosphate synthase and prenyltransferases, leading to enhanced isoprenylation and activation of N-Ras; elevated N-Ras activity induces DNA damage response and p130-dependent cellular senescence in Rb-deficient cells.\",\n      \"method\": \"Genetic mouse model (Rb heterozygous), E2F-dependent gene expression analysis, N-Ras activity assay, senescence assays\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic model combined with biochemical pathway analysis; single lab, multiple readouts\",\n      \"pmids\": [\"19345325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Acquired resistance to PLX4032 (B-RAF V600E inhibitor) develops via N-RAS mutations (but not secondary B-RAF mutations), causing high levels of activated N-RAS that lead to significant MAPK pathway reactivation; knockdown of N-RAS reduced growth of resistant cells, and overexpression of N-RAS(Q61K) conferred PLX4032 resistance to sensitive cells.\",\n      \"method\": \"Drug-resistant cell line derivation, N-RAS mutation detection, N-RAS knockdown, N-RAS overexpression, MAPK pathway activity assays, validation in patient-derived biopsies\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function and gain-of-function with mechanistic pathway readout, validated in clinical specimens; reciprocal experimental design\",\n      \"pmids\": [\"21107323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TLR agonists at the plasma membrane (TLR 1, 2, 4, 5, 6) rapidly activate N-Ras but not other Ras isoforms in cholangiocytes; activated N-Ras signals through ERK1/2 to drive IL-6 secretion and cholangiocyte proliferation; TRAF6 depletion does not affect N-Ras activation, indicating a TRAF6-independent TLR-to-N-Ras pathway.\",\n      \"method\": \"Ras activation assay (isoform-selective), RNAi knockdown of N-Ras and TRAF6, luciferase reporter for IL-6 promoter, MEK/ERK inhibitors, proliferation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-selective activation assay plus RNAi with multiple downstream readouts; single lab\",\n      \"pmids\": [\"21757746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Clustering of raft-associated proteins (GPI-anchored HA-GPI or fibronectin receptors) selectively enhances plasma membrane-to-cytoplasm exchange of GTP-bound N-Ras in a cholesterol-dependent manner; this effect depends strictly on depalmitoylation; HA-GPI clustering enhances Golgi accumulation and EGF-stimulated N-Ras-GTP signaling.\",\n      \"method\": \"Patch-FRAP, FRAP beam-size analysis, electron microscopy, cholesterol depletion, palmitoylation-deficient mutants\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal biophysical methods (patch-FRAP, EM) with mutagenesis (palmitoylation-deficient mutants) and pharmacological validation; single lab\",\n      \"pmids\": [\"21807892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Membrane binding of lipidated N-Ras induces new conformational substates in the protein (detected as novel FTIR bands) beyond those induced by nucleotide binding; the membrane acts as an active interaction partner that controls G-domain orientation and selection of signaling conformations.\",\n      \"method\": \"Pressure-modulation FTIR spectroscopy, ATR-FTIR and IRRAS measurements on lipidated N-Ras in solution and membrane-bound states\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — rigorous biophysical method (pressure-FTIR) revealing novel conformational substates, but single lab and no mutagenesis follow-up reported\",\n      \"pmids\": [\"22203965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Mutant N-RAS protects colorectal cancer cells from apoptosis via activation of a noncanonical MAPK pathway signaling through STAT3; MEK inhibition selectively induces apoptosis in colonic tumors expressing mutant N-RAS.\",\n      \"method\": \"Genetically engineered mouse model, STAT3 pathway analysis, MEK inhibitor treatment, apoptosis assays\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic model with defined mechanistic pathway (N-RAS → noncanonical MAPK → STAT3) and pharmacological validation; single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"23274911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Palmitoylation of N-Ras is required for its activation by growth factor agonists; only palmitoylated N-Ras becomes GTP-loaded in response to EGF; palmitoylation-deficient N-Ras localizes to endomembranes, fails to be activated by agonists, and cannot sustain EGF- or serum-elicited mitogenic signaling.\",\n      \"method\": \"Palmitoylation-deficient N-Ras mutants, GTP-loading assay, live-cell Ras-GTP imaging, palmitate content analysis of activated N-Ras, dominant-negative Ras experiments\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mutagenesis with multiple orthogonal methods (GTP assay, live imaging, palmitate content); single lab\",\n      \"pmids\": [\"23758196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Wild-type H-Ras or N-Ras downregulation in mutant K-Ras cancer cells leads to hyperactivation of Erk/p90RSK and PI3K/Akt pathways and inhibitory phosphorylation of Chk1 at Ser280, abrogating ATR/Chk1 DNA damage checkpoint activation and sensitizing cells to DNA-damaging chemotherapeutics.\",\n      \"method\": \"RNAi knockdown, pathway phosphorylation analysis, Chk1 activity assays, chemotherapeutic sensitivity assays in vitro and in vivo\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with specific molecular pathway readout (Chk1 phosphorylation); single lab, multiple methods\",\n      \"pmids\": [\"24525237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ABHD17 family proteins act as protein depalmitoylases that accelerate palmitate turnover on N-Ras; ABHD17 catalytic activity is required for N-Ras depalmitoylation and relocalization to internal cellular membranes. APT1 and APT2 inhibition (with Palmostatin B) does not affect palmitate turnover on N-Ras, whereas ABHD17 proteins do.\",\n      \"method\": \"Dual pulse-chase strategy comparing palmitate and protein half-lives, activity profiling, shRNA knockdown, catalytic mutant analysis\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct palmitate turnover assay combined with catalytic mutant analysis and subcellular localization readout; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"26701913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Singly palmitoylated N-Ras is polarized within the Golgi with relative paucity at the trans-Golgi, in contrast to doubly palmitoylated H-Ras which distributes throughout Golgi stacks; palmitoylation mutants show that degree of acylation controls sub-Golgi distribution.\",\n      \"method\": \"Confocal live-cell fluorescent imaging, immunogold electron microscopy, palmitoylation mutant analysis\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct imaging with two orthogonal methods (confocal + EM) plus mutagenesis; single lab\",\n      \"pmids\": [\"25158650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Wild-type N-Ras, but not K-Ras, induces IL-8 secretion by binding and activating the cytoplasmic pool of JAK2; IL-8 then acts in autocrine/paracrine fashion on cancer cells and stromal fibroblasts to promote basal-like breast cancer progression.\",\n      \"method\": \"N-RAS knockdown/overexpression, co-immunoprecipitation of N-Ras with JAK2, cytokine profiling, IL-8 reporter assays, in vivo tumor growth\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP demonstrating N-Ras/JAK2 interaction with isoform specificity (K-Ras negative) and functional downstream readout; single lab\",\n      \"pmids\": [\"26166574\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"VPS35, a component of the retromer coat, binds to farnesylated but not palmitoylated N-Ras in the cytosol; this interaction is farnesyl-dependent and GTP-independent. VPS35 silencing increases N-Ras association with cytoplasmic vesicles, diminishes GTP loading of Ras, and inhibits MAPK signaling and growth of N-Ras-dependent melanoma cells.\",\n      \"method\": \"Affinity purification, mass spectrometry identification, co-immunoprecipitation, farnesyl/palmitoyl mutant analysis, VPS35 siRNA knockdown, subcellular fractionation\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — affinity purification + MS identification + reciprocal co-IP with mutant validation and functional consequence; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"27502489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"N-Ras, H-Ras, and K-Ras show distinct intrinsic GTP hydrolysis rates under identical conditions; the presence of the Raf-RBD further differentiates isoform kinetics; crystal structure of N-Ras bound to a GTP analogue reveals structural features accounting for allosteric isoform-specific differences despite identical active sites.\",\n      \"method\": \"Enzyme kinetic assays with purified recombinant proteins, crystal structure determination of N-Ras·GTP analogue complex\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted in vitro enzymatic assay combined with crystal structure; single lab but two orthogonal methods (kinetics + structure)\",\n      \"pmids\": [\"28630043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"N-ras proto-oncogene suppresses the malignant phenotype: lack of wild-type N-ras alleles in mice favors thymic lymphoma development, while overexpression of wild-type N-ras protects against lymphomagenesis; introduction of wild-type N-ras into N-ras-deficient tumor cells decreases growth in low serum and soft agar.\",\n      \"method\": \"N-ras knockout mouse model, transgenic overexpression, in vitro growth assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic in vivo and in vitro loss-of-function/gain-of-function experiments; single lab, multiple model systems\",\n      \"pmids\": [\"12154063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"N-ras is specifically required for normal T-cell function: N-ras knockout mice have reduced CD8 single positive thymocytes, decreased thymocyte proliferation, defective T-cell receptor Ras signaling activation, reduced IL-2 production upon activation, and increased susceptibility to influenza infection.\",\n      \"method\": \"N-ras knockout mouse model, flow cytometry, thymocyte proliferation assay, Ras signaling/activation assays, in vivo influenza challenge\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knockout with multiple orthogonal phenotypic and molecular readouts, in vitro and in vivo validation; single lab\",\n      \"pmids\": [\"12670913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Deletion of N-ras rescues a unique subset of developmental defects (skeletal muscle differentiation, MCK gene expression) caused by Rb nullizygosity in mice, and potentiates MyoD transcriptional activity, demonstrating that N-ras and Rb operate in a common pathway controlling differentiation.\",\n      \"method\": \"Double knockout (Rb−/−; N-ras−/−) mouse model, histological analysis, MCK expression, MyoD transcriptional activity assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in vivo with multiple molecular readouts; establishes pathway relationship between N-ras and Rb\",\n      \"pmids\": [\"12861012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"N-RAS and H-RAS (but not K-RAS) are required for TGF-β1-mediated fibroblast proliferation and ECM synthesis regulation; H-ras−/−/N-ras−/− double knockout fibroblasts show increased ECM synthesis and decreased ERK activation, with compensatory Akt upregulation; MEK/ERK mediates Ras-dependent proliferation while PI3K-Akt mediates ECM synthesis control.\",\n      \"method\": \"Double knockout (H-ras−/−/N-ras−/−) mouse embryonic fibroblasts, TGF-β1 stimulation, ERK and Akt activation assays, pathway inhibitors, proliferation and ECM assays\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with pathway dissection using inhibitors; single lab, multiple readouts\",\n      \"pmids\": [\"16624289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Endogenous N-RAS physically interacts with gelsolin; in cells expressing wild-type K-RAS, N-RAS subserves an antiapoptotic role that is compromised by the presence of oncogenic K-RAS; mutant K-RAS elevates GTP-bound N-RAS and alters modulation of the N-RAS:gelsolin complex following apoptotic challenge.\",\n      \"method\": \"Co-immunoprecipitation of endogenous N-RAS and gelsolin, isogenic cell lines with wild-type vs. mutant K-RAS, apoptosis assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP of endogenous proteins with functional apoptosis readout in isogenic cell lines; single lab\",\n      \"pmids\": [\"17130841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Galectin-3 N-terminal domain interacts with and inhibits RasGRP4-mediated GTP loading specifically on N-Ras and H-Ras but not K-Ras; EGF-stimulated GTP loading of N-Ras is blocked in high Gal-3-expressing cells; PMA activation of RasGRPs or Gal-3 shRNA knockdown increases N-Ras-GTP levels.\",\n      \"method\": \"Co-immunoprecipitation, RasGRP4 GEF activity assay on N-Ras, Gal-3 shRNA knockdown, Ras activation assays\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP combined with functional GEF assay and RNAi; single lab, multiple approaches\",\n      \"pmids\": [\"18413234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TCR-induced activation of endogenous Ras proceeds exclusively at the plasma membrane, not at the Golgi or other endomembranes; palmitoylation of N-Ras is critical for its activation by TCR signals, as palmitoylation-deficient N-Ras confined to endomembranes is not activated.\",\n      \"method\": \"Live-cell Ras-GTP imaging with novel affinity probes in Jurkat and primary T cells, palmitoylation-deficient Ras mutants, immunological synapse imaging\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — live-cell GTP imaging with palmitoylation mutants and primary cell validation; single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"20713885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"H-ras and N-ras are dispensable for thymocyte development and mature T-cell activation but are critical controllers of Th1 responses: CD4+ T cells from H-ras- or N-ras-deficient mice show markedly decreased IFN-γ production and impaired T-bet induction after TCR stimulation; in vivo Th1 immunity against L. major is defective.\",\n      \"method\": \"H-ras−/− and N-ras−/− mouse models, T-cell activation assays, cytokine production, T-bet expression, in vivo L. major infection\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knockout with specific molecular pathway readout (T-bet/IFN-γ) validated in vitro and in vivo; single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"21444916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NRAS(G12V) mutant melanocytes display pronounced PI3K/AKT signaling while NRAS(Q61L) mutant melanocytes display pronounced MAPK signaling; CK2α is significantly overrepresented in NRAS(Q61) mutant cells and these cells are more sensitive to CK2α pharmacologic inhibition.\",\n      \"method\": \"SILAC-based phosphoproteomics, kinase prediction modeling, pharmacological CK2α inhibition, patient sample validation at mRNA and protein level\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphoproteomic profiling with pharmacological validation; single lab, two orthogonal methods\",\n      \"pmids\": [\"27251789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Transcription of unr (upstream of N-ras) negatively regulates N-ras expression in vivo through transcriptional interference; deletion of the unr promoter in mice increases N-ras mRNA accumulation by 20–65%.\",\n      \"method\": \"Homologous recombination deletion of unr promoter in mouse ES cells, RNase protection assays for N-ras mRNA levels\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic deletion with direct mRNA quantification; single lab\",\n      \"pmids\": [\"9450542\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NRAS encodes a small GTPase that cycles between GDP-bound (inactive) and GTP-bound (active) states; point mutations at codons 12, 13, or 61 reduce intrinsic GTPase activity and lock the protein in its active state, enabling constitutive downstream signaling through Raf/MEK/ERK and PI3K/AKT pathways. Membrane association and signaling competency require sequential prenylation (farnesylation) and palmitoylation: DHHC9·GCP16 palmitoylates N-Ras at the Golgi, directing it to the plasma membrane, while ABHD17 family depalmitoylases remove the palmitate to allow redistribution; VPS35 retromer serves as a cytosolic chaperone for farnesylated, non-palmitoylated N-Ras to regulate its trafficking. N-Ras activation occurs exclusively at the plasma membrane in a palmitoylation-dependent manner, and the membrane itself allosterically controls the conformational states of N-Ras. Compared to K-Ras and H-Ras, N-Ras has distinct intrinsic GTP hydrolysis kinetics determined by allosteric effects, preferentially associates with liquid-disordered lipid domains, and is uniquely activated downstream of plasma membrane Toll-like receptors and TCR signaling; N-Ras uniquely binds and activates cytoplasmic JAK2 to drive IL-8 secretion. Physiologically, N-Ras is required for T-cell function (CD8 thymocyte development, IL-2 production, Th1/IFN-γ responses) and cooperates with pRb in controlling differentiation; its proto-oncogenic form can suppress malignant transformation, whereas activating mutations drive hematopoietic malignancies and melanoma via MAPK reactivation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NRAS encodes a small GTPase that cycles between GDP- and GTP-bound states and drives proliferation, differentiation, and immune signaling through Raf/MEK/ERK and PI3K/AKT outputs [#0, #29]. Oncogenic activation arises from point mutations at codons 12, 13, or 61 that reduce intrinsic GTPase activity and lock the protein in its active state; reduced hydrolysis rather than altered nucleotide binding underlies transformation [#0, #3], and such mutations suppress differentiation programs such as myoblast fusion [#4] while driving hematopoietic malignancy and melanoma, including acquired resistance to B-RAF inhibition through MAPK reactivation [#14] and STAT3-dependent apoptosis evasion in colorectal tumors [#18]. Signaling competency depends on lipid-directed trafficking: N-Ras is farnesylated, or alternatively geranylgeranylated when farnesyltransferase is blocked [#5], and is then S-palmitoylated by the Golgi-resident DHHC9·GCP16 complex to target it to the plasma membrane [#11, #6], where it preferentially partitions into liquid-disordered lipid domains [#12] and adopts membrane-controlled signaling conformations [#17]. Palmitate is removed by ABHD17-family depalmitoylases to permit redistribution [#21], while the VPS35 retromer binds farnesylated, non-palmitoylated N-Ras as a cytosolic chaperone governing trafficking and GTP loading [#24]. Activation occurs exclusively at the plasma membrane in a palmitoylation-dependent manner downstream of growth factor receptors, TCR engagement, and plasma-membrane Toll-like receptors [#19, #32, #15]. N-Ras is physiologically required for T-cell function, including CD8 thymocyte development, IL-2 production, and Th1/IFN-γ responses [#27, #33], and operates in a common differentiation pathway with pRb [#28]. Distinct from K-Ras and H-Ras, N-Ras has isoform-specific intrinsic hydrolysis kinetics set by allosteric structural features [#25] and uniquely binds and activates cytoplasmic JAK2 to drive IL-8 secretion [#23].\",\n  \"teleology\": [\n    {\n      \"year\": 1983,\n      \"claim\": \"Established that a single point mutation is sufficient to convert N-ras into an oncogene, defining codon 61 (alongside codon 12) as an activation hotspot.\",\n      \"evidence\": \"Gene cloning, sequencing, and NIH 3T3 transformation assay\",\n      \"pmids\": [\"6616621\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the biochemical defect caused by the mutation\", \"No mechanism linking the mutant to downstream effectors\"]\n    },\n    {\n      \"year\": 1985,\n      \"claim\": \"Confirmed across melanoma and rhabdomyosarcoma that codon 61 substitutions alone confer transforming activity, generalizing the activation mechanism beyond a single tumor type.\",\n      \"evidence\": \"Cloning, sequencing, and transfection/transformation assays in tumor-derived lines\",\n      \"pmids\": [\"3158613\", \"3887133\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not quantify how the mutation alters GTPase function\", \"No downstream pathway readout\"]\n    },\n    {\n      \"year\": 1987,\n      \"claim\": \"Pinned the molecular basis of oncogenicity to reduced GTP hydrolysis rather than altered nucleotide binding, and showed oncogenic N-Ras blocks differentiation independent of proliferation.\",\n      \"evidence\": \"Recombinant mutant proteins with in vitro GTPase/binding assays, microinjection, and differentiation assays in C2 myoblasts\",\n      \"pmids\": [\"3550423\", \"3600660\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the downstream effectors mediating differentiation block\", \"No structural explanation for the GTPase defect\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Defined how N-Ras achieves membrane association, showing alternative geranylgeranylation under FTI treatment and palmitoylation-dependent kinetic trapping at the plasma membrane.\",\n      \"evidence\": \"Cell-based prenylation/fractionation under FTI, and lipidated peptide reconstitution with fluorescence microscopy and pharmacological perturbation\",\n      \"pmids\": [\"9162087\", \"9335573\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Palmitoyltransferase enzyme not yet identified\", \"Did not address how depalmitoylation reverses targeting\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identified transcriptional interference from the upstream unr gene as a regulator of N-ras mRNA levels.\",\n      \"evidence\": \"Homologous recombination deletion of the unr promoter in mice with RNase protection of N-ras mRNA\",\n      \"pmids\": [\"9450542\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Modest effect size (20-65%)\", \"Physiological consequence of altered N-ras levels not tested\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrated isoform-selective upstream and downstream coupling, with the hypervariable domain dictating GEF specificity and N-Ras contributing to MAPK output even in H-ras-transformed cells.\",\n      \"evidence\": \"In vivo GEF selectivity assays, co-IP with Raf-1, and antisense knockdown of c-N-Ras\",\n      \"pmids\": [\"9430727\", \"9525741\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab co-IP without structural validation\", \"Mechanism of differential GEF engagement at residue level not resolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Showed oncogenic N-Ras remodels the Golgi and cytoskeleton and enhances secretory transport, linking it to organelle physiology beyond canonical signaling.\",\n      \"evidence\": \"Conditional N-Ras(K61) expression in NRK cells with EM, stereology, transport assays, and PLA2 inhibition\",\n      \"pmids\": [\"9914160\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Effector pathway connecting N-Ras to Golgi collapse unclear\", \"PLA2 inhibitor effect only partial\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Distinguished N-Ras from K-Ras by negative regulation, showing calmodulin binds and modulates K-Ras but not N-Ras.\",\n      \"evidence\": \"Calmodulin affinity chromatography and Ras activation assays across isoforms\",\n      \"pmids\": [\"11585916\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Negative result for N-Ras; does not define an N-Ras-specific regulator\", \"Single-lab biochemistry\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined physiological roles of N-ras in tumor suppression, T-cell immunity, and Rb-dependent differentiation through genetic loss-of-function in mice.\",\n      \"evidence\": \"N-ras knockout, transgenic overexpression, and Rb;N-ras double-knockout mouse models with phenotypic and molecular readouts\",\n      \"pmids\": [\"12154063\", \"12670913\", \"12861012\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic link between N-Ras and the Rb/MyoD axis not biochemically resolved\", \"Compensation by other Ras isoforms not fully excluded\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified the enzyme responsible for N-Ras palmitoylation, establishing DHHC9·GCP16 as a Golgi-localized palmitoyltransferase with substrate specificity for N-Ras and H-Ras.\",\n      \"evidence\": \"Reconstituted in vitro palmitoyltransferase assay with substrate specificity testing, co-IP, and Golgi localization microscopy\",\n      \"pmids\": [\"16000296\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define how depalmitoylation is achieved\", \"In vivo requirement for N-Ras signaling not tested in this study\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Extended N-Ras roles to TGF-β-driven fibroblast biology and revealed gelsolin as a physical partner mediating an antiapoptotic function modulated by K-Ras status.\",\n      \"evidence\": \"H-ras/N-ras double-knockout fibroblasts with pathway dissection, and co-IP of endogenous N-Ras with gelsolin in isogenic K-RAS lines\",\n      \"pmids\": [\"16624289\", \"17130841\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab co-IP for the gelsolin interaction\", \"Direct contribution of gelsolin binding to apoptosis resistance not isolated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Provided biophysical basis for membrane preference, showing lipidated N-Ras favors liquid-disordered domains and phase boundaries.\",\n      \"evidence\": \"Two-photon fluorescence microscopy and AFM on giant unilamellar vesicles with fully lipidated N-Ras\",\n      \"pmids\": [\"16390147\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconstituted model system; in-cell phase behavior not directly shown\", \"Functional consequence of domain preference for signaling not addressed here\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified galectin-3 as an isoform-selective negative regulator of N-Ras/H-Ras activation by inhibiting RasGRP4-mediated GTP loading.\",\n      \"evidence\": \"Co-IP, RasGRP4 GEF activity assays, and Gal-3 shRNA knockdown with Ras activation readouts\",\n      \"pmids\": [\"18413234\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab mechanism\", \"Structural basis of selective inhibition not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Linked Rb loss to N-Ras activation via E2F-driven prenyltransferase upregulation, coupling N-Ras hyperactivity to senescence and DNA damage response.\",\n      \"evidence\": \"Rb-heterozygous mouse model with E2F target analysis, N-Ras activity assays, and senescence readouts\",\n      \"pmids\": [\"19345325\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal sufficiency of prenylation increase not fully isolated\", \"Single-model system\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated activation occurs exclusively at the plasma membrane in a palmitoylation-dependent manner downstream of TCR signaling.\",\n      \"evidence\": \"Live-cell Ras-GTP imaging with affinity probes and palmitoylation-deficient mutants in Jurkat and primary T cells\",\n      \"pmids\": [\"20713885\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"GEF responsible for plasma-membrane activation not identified\", \"Did not resolve spatial dynamics relative to the synapse at molecular detail\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Established N-RAS mutation as a clinically relevant mechanism of acquired B-RAF inhibitor resistance through MAPK reactivation.\",\n      \"evidence\": \"Resistant cell derivation, N-RAS knockdown and Q61K overexpression with MAPK readouts, validated in patient biopsies\",\n      \"pmids\": [\"21107323\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address combination strategies to overcome resistance\", \"Other resistance routes not excluded\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Connected plasma-membrane Toll-like receptor signaling to selective N-Ras activation driving IL-6 secretion and proliferation via a TRAF6-independent route.\",\n      \"evidence\": \"Isoform-selective Ras activation assays, RNAi of N-Ras and TRAF6, and IL-6 reporter/proliferation assays in cholangiocytes\",\n      \"pmids\": [\"21757746\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The adaptor coupling TLRs to N-Ras unidentified\", \"Single cell-type context\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed the membrane is an active conformational partner that, with depalmitoylation and raft clustering, governs N-Ras conformation and plasma-membrane-to-cytoplasm exchange.\",\n      \"evidence\": \"Pressure-FTIR conformational analysis and patch-FRAP/EM with palmitoylation-deficient mutants and cholesterol depletion\",\n      \"pmids\": [\"22203965\", \"21807892\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"FTIR conformer assignments lack mutagenesis follow-up\", \"Single-lab biophysical methods\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined a noncanonical mutant N-RAS survival pathway through STAT3, identifying MEK inhibition as a selective vulnerability in mutant-N-RAS colorectal tumors.\",\n      \"evidence\": \"Genetically engineered mouse model with STAT3 pathway analysis, MEK inhibition, and apoptosis assays\",\n      \"pmids\": [\"23274911\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular link from N-RAS to STAT3 not fully mapped\", \"Generality beyond colorectal context untested here\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established palmitoylation as a strict requirement for agonist-driven N-Ras GTP loading and sustained mitogenic signaling.\",\n      \"evidence\": \"Palmitoylation-deficient mutants with GTP-loading assays, live-cell imaging, and palmitate content analysis of activated N-Ras\",\n      \"pmids\": [\"23758196\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the depalmitoylase governing the cycle\", \"Spatial coordination with the palmitoyltransferase not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Revealed a tumor-suppressive function of wild-type N-Ras/H-Ras in mutant-K-Ras cells, maintaining the ATR/Chk1 DNA damage checkpoint.\",\n      \"evidence\": \"RNAi knockdown with pathway phosphorylation analysis and chemosensitivity assays in vitro and in vivo\",\n      \"pmids\": [\"24525237\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism connecting wild-type Ras to Chk1 Ser280 phosphorylation indirect\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Resolved the depalmitoylation arm of the trafficking cycle, identifying ABHD17 (not APT1/2) as the depalmitoylase driving N-Ras palmitate turnover and relocalization, and refined sub-Golgi distribution by acylation degree.\",\n      \"evidence\": \"Pulse-chase palmitate/protein half-life comparison, catalytic mutants, shRNA, and confocal/EM imaging of palmitoylation mutants\",\n      \"pmids\": [\"26701913\", \"25158650\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ABHD17 is targeted to N-Ras pools not defined\", \"Coupling of depalmitoylation kinetics to signaling output not quantified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified a unique, isoform-specific effector function in which wild-type N-Ras binds and activates cytoplasmic JAK2 to drive IL-8 secretion and tumor progression.\",\n      \"evidence\": \"N-RAS knockdown/overexpression, N-Ras·JAK2 co-IP, cytokine profiling, and in vivo tumor growth\",\n      \"pmids\": [\"26166574\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab co-IP; direct binding interface not defined\", \"Dependence on GTP state and membrane context untested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linked specific N-RAS mutation classes to divergent signaling outputs and a CK2α vulnerability in codon-61 mutant melanoma.\",\n      \"evidence\": \"SILAC phosphoproteomics, kinase prediction, pharmacological CK2α inhibition, and patient sample validation\",\n      \"pmids\": [\"27251789\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which Q61 versus G12 mutations bias pathway choice unresolved\", \"Single-lab profiling\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified VPS35/retromer as a cytosolic chaperone for farnesylated, non-palmitoylated N-Ras required for its GTP loading and oncogenic signaling.\",\n      \"evidence\": \"Affinity purification/MS, reciprocal co-IP with farnesyl/palmitoyl mutants, VPS35 silencing, and fractionation in melanoma cells\",\n      \"pmids\": [\"27502489\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How VPS35 hands off N-Ras to the palmitoylation machinery not defined\", \"Structural basis of farnesyl recognition unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Provided the structural and kinetic basis for isoform-specific behavior, showing N-Ras has distinct intrinsic hydrolysis kinetics set by allosteric features despite an identical active site.\",\n      \"evidence\": \"Enzyme kinetics with purified recombinant Ras isoforms and crystal structure of N-Ras bound to a GTP analogue\",\n      \"pmids\": [\"28630043\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Allosteric residues responsible not functionally validated by mutagenesis\", \"In-cell relevance of kinetic differences not directly tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how the spatial palmitoylation/depalmitoylation cycle, VPS35 chaperoning, and membrane-controlled conformations are integrated to dictate which effector arm (Raf/MEK/ERK, PI3K/AKT, JAK2, or STAT3) a given N-Ras mutant engages in a specific cellular context.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified spatiotemporal model linking trafficking machinery to effector selection\", \"GEFs activating N-Ras at the plasma membrane downstream of TCR/TLR not identified\", \"Mutation-class-specific effector bias mechanism unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003924\", \"supporting_discovery_ids\": [3, 25]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 19, 32]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [6, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6, 19, 32]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [11, 22]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 14, 19]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [14, 18]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [27, 33, 32]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 28]}\n    ],\n    \"complexes\": [\"VPS35/retromer (as bound cargo)\"],\n    \"partners\": [\"RAF1\", \"JAK2\", \"VPS35\", \"GSN\", \"LGALS3\", \"DHHC9\", \"GCP16\", \"ABHD17\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}